.png)
.png)
.png)
.png)
About Us
Founded in 2015 and headquartered in Budapest, SigmaDrugs Ltd. is a clinical-stage biotech innovator dedicated to transforming the treatment landscape for chronic fibrotic diseases and organ transplantation.
We harness the therapeutic potential of Sigma-1 receptor agonists to develop novel, disease-modifying treatments for high-unmet-need conditions, including glaucoma (ocular fibrosis), idiopathic pulmonary fibrosis, and end-stage renal failure. Backed by robust preclinical data, our core therapeutic platform holds granted patents across major global markets, including the US, Europe, Israel, China, and Japan.
In parallel, SigmaDrugs is advancing a proprietary organ preservation solution designed to protect grafts during transplantation. By reducing ischemia-reperfusion injury and enhancing graft viability, our technology aims to improve patient outcomes and help alleviate the global donor organ shortage.
Our vision
In collaboration with global partners, SigmaDrugs is committed to bringing next-generation therapies to market that address tissue remodeling and critical challenges in organ survival.
Our vision centers on three high-impact clinical targets: preventing vision loss in glaucoma by targeting ocular fibrosis, halting progressive tissue scarring in pulmonary fibrosis, and revolutionizing organ transplantation through advanced preservation solutions that protect graft viability.
By successfully commercializing these innovations, we aim to transform patient care across ophthalmology, pulmonology, and transplant medicine. Ultimately, we seek to deliver accessible, cost-effective solutions that improve quality of life for millions while offering sustainable savings to healthcare systems globally.